{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:08:45Z","timestamp":1790352525897,"version":"4.1.0"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011841","name":"Xinxiang Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bcp.2026.117897","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:17:54Z","timestamp":1773825474000},"page":"117897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Mechanism and interventions of the bile acid-gut-liver axis imbalance in the progression of non-alcoholic fatty liver disease"],"prefix":"10.1016","volume":"249","author":[{"given":"Ya-qi","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-xi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-lu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ting","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-chu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-qian","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bcp.2026.117897_b0005","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American heart association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"12","key":"10.1016\/j.bcp.2026.117897_b0010","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.dld.2020.09.013","article-title":"NAFLD, MAFLD and DAFLD","volume":"52","author":"Mantovani","year":"2020","journal-title":"Dig. Liver Dis."},{"issue":"2","key":"10.1016\/j.bcp.2026.117897_b0015","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0020","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s13098-025-01932-0","article-title":"Global burden of chronic liver disease due to NAFLD from 2012 to 2021: a trend, decomposition, and health inequality analysis","volume":"17","author":"Wu","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2026.117897_b0025","first-page":"S24","article-title":"Dietary patterns in non-alcoholic fatty liver disease (NAFLD): Stay on the straight and narrow path!","volume":"34","author":"Katsiki","year":"2022","journal-title":"Clin. Investig. Arterioscler"},{"issue":"7","key":"10.1016\/j.bcp.2026.117897_b0030","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1080\/17461391.2019.1571114","article-title":"Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): roles of oxidative stress and inflammation","volume":"19","author":"Farzanegi","year":"2019","journal-title":"Eur. J. Sport Sci."},{"issue":"11","key":"10.1016\/j.bcp.2026.117897_b0035","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/liv.15404","article-title":"Management of NAFLD in primary care settings","volume":"42","author":"Wong","year":"2022","journal-title":"Liver Int."},{"key":"10.1016\/j.bcp.2026.117897_b0040","doi-asserted-by":"crossref","unstructured":"S. Raza, S. Rajak, A. Upadhyay, A. Tewari, R. Anthony Sinha, Current treatment paradigms and emerging therapies for NAFLD\/NASH, Front Biosci (Landmark Ed) 26(2) (2021) 206-237.","DOI":"10.2741\/4892"},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0045","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1186\/s12876-025-04436-3","article-title":"Therapeutic potential of Akkermansia muciniphila in non-alcoholic fatty liver disease: a systematic review","volume":"25","author":"Asghari","year":"2025","journal-title":"BMC Gastroenterol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism","volume":"24","author":"Wahlstr\u00f6m","year":"2016","journal-title":"Cell Metab."},{"issue":"8","key":"10.1016\/j.bcp.2026.117897_b0055","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00018-019-03011-w","article-title":"The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)","volume":"76","author":"Safari","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0060","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00010.2008","article-title":"Role of bile acids and bile acid receptors in metabolic regulation","volume":"89","author":"Lefebvre","year":"2009","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.bcp.2026.117897_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20020395","article-title":"Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature","volume":"20","author":"Milosevic","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2026.117897_b0070","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117897_b0075","doi-asserted-by":"crossref","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","article-title":"Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy","volume":"318","author":"Chiang","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"11","key":"10.1016\/j.bcp.2026.117897_b0080","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41579-023-00904-3","article-title":"The gut-liver axis and gut microbiota in health and liver disease","volume":"21","author":"Hsu","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117897_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/nu15061323","article-title":"Small intestinal bacterial overgrowth and non-alcoholic fatty liver disease: what do we know in 2023?","volume":"15","author":"Gudan","year":"2023","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.bcp.2026.117897_b0090","article-title":"Intestinal barrier dysfunction and gut microbiota in non-alcoholic fatty liver disease: assessment mechanisms, and therapeutic considerations","volume":"13","author":"Long","year":"2024","journal-title":"Biology (Basel)"},{"issue":"11","key":"10.1016\/j.bcp.2026.117897_b0095","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/j.bbamem.2017.08.019","article-title":"Planar bile acids in health and disease","volume":"1859","author":"Shiffka","year":"2017","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.bcp.2026.117897_b0100","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","article-title":"The enzymes, regulation, and genetics of bile acid synthesis","volume":"72","author":"Russell","year":"2003","journal-title":"Annu. Rev. Biochem"},{"issue":"3","key":"10.1016\/j.bcp.2026.117897_b0105","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2003.11.006","article-title":"Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms","volume":"40","author":"Chiang","year":"2004","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117897_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041780","article-title":"Physiology and physical chemistry of bile acids","volume":"22","author":"di Gregorio","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2026.117897_b0115","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/pr.113.008201","article-title":"Bile acid signaling in metabolic disease and drug therapy","volume":"66","author":"Li","year":"2014","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.bcp.2026.117897_b0120","doi-asserted-by":"crossref","DOI":"10.3390\/nu13031018","article-title":"The gut-liver axis in cholestatic liver diseases","volume":"13","author":"Blesl","year":"2021","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.bcp.2026.117897_b0125","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12466","article-title":"Gut-liver axis: potential mechanisms of action of food-derived extracellular vesicles","volume":"13","author":"Zhang","year":"2024","journal-title":"J. Extracell Vesicles"},{"key":"10.1016\/j.bcp.2026.117897_b0130","article-title":"Bile acid detection techniques and bile acid-related diseases","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Physiol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117897_b0135","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/j.2040-4603.2013.tb00517.x","article-title":"Bile acid metabolism and signaling","volume":"3","author":"Chiang","year":"2013","journal-title":"Compr. Physiol."},{"issue":"23","key":"10.1016\/j.bcp.2026.117897_b0140","doi-asserted-by":"crossref","first-page":"11432","DOI":"10.1039\/D4FO03353A","article-title":"Abnormal enterohepatic circulation of bile acids caused by fructooligosaccharide supplementation along with a high-fat diet","volume":"15","author":"Zeng","year":"2024","journal-title":"Food Funct."},{"key":"10.1016\/j.bcp.2026.117897_b0145","doi-asserted-by":"crossref","first-page":"617676","DOI":"10.3389\/fnut.2020.617676","article-title":"Lactobacillus delbrueckii interfere with bile acid enterohepatic circulation to regulate cholesterol Metabolism of Growing-Finishing Pigs via Its Bile Salt Hydrolase Activity","volume":"7","author":"Hou","year":"2020","journal-title":"Front Nutr."},{"key":"10.1016\/j.bcp.2026.117897_b0150","doi-asserted-by":"crossref","unstructured":"Y. Li, L. Chen, L. Li, C. Sottas, S.K. Petrillo, A. Lazaris, P. Metrakos, H. Wu, Y. Ishida, T. Saito, L. Golden-Mason, H.R. Rosen, J.J. Wolff, C.I. Silvescu, S. Garza, G. Cheung, T. Huang, J. Fan, M. Culty, B. Stiles, K. Asahina, V. Papadopoulos, Cholesterol-binding translocator protein TSPO regulates steatosis and bile acid synthesis in nonalcoholic fatty liver disease, iScience 24(5) (2021).","DOI":"10.1016\/j.isci.2021.102457"},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/j.2040-4603.2020.tb00108.x","article-title":"Intestinal absorption of bile acids in health and disease","volume":"10","author":"Ticho","year":"2019","journal-title":"Compr. Physiol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117897_b0160","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.autrev.2017.07.002","article-title":"Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases","volume":"16","author":"Li","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.bcp.2026.117897_b0165","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/imm.13672","article-title":"Effect of gut flora mediated-bile acid metabolism on intestinal immune microenvironment","volume":"170","author":"Zhang","year":"2023","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0170","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12876-020-01195-1","article-title":"Intestinal flora imbalance affects bile acid metabolism and is associated with gallstone formation","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.bcp.2026.117897_b0175","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.3389\/fmicb.2018.02209","article-title":"Dietary bile salt types influence the composition of biliary bile acids and gut microbiota in grass carp","volume":"9","author":"Xiong","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bcp.2026.117897_b0180","doi-asserted-by":"crossref","unstructured":"Y. Li, L. Chen, L. Li, C. Sottas, S.K. Petrillo, A. Lazaris, P. Metrakos, H. Wu, Y. Ishida, T. Saito, L. Golden-Mason, H.R. Rosen, J.J. Wolff, C.I. Silvescu, S. Garza, G. Cheung, T. Huang, J. Fan, M. Culty, B. Stiles, K. Asahina, V. Papadopoulos, Cholesterol-binding translocator protein TSPO regulates steatosis and bile acid synthesis in nonalcoholic fatty liver disease, iScience 24(5) (2021) 102457.","DOI":"10.1016\/j.isci.2021.102457"},{"key":"10.1016\/j.bcp.2026.117897_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.125662","article-title":"The polysaccharides from Auricularia auricula alleviate non-alcoholic fatty liver disease via modulating gut microbiota and bile acids metabolism","volume":"246","author":"Shu","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bcp.2026.117897_b0190","doi-asserted-by":"crossref","first-page":"914247","DOI":"10.3389\/fcimb.2022.914247","article-title":"Comprehensive analysis of gut microbiota and fecal bile acid profiles in children with biliary atresia","volume":"12","author":"Yang","year":"2022","journal-title":"Front Cell Infect. Microbiol."},{"issue":"8","key":"10.1016\/j.bcp.2026.117897_b0195","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8081089","article-title":"Gut microbiota and risk of persistent nonalcoholic fatty liver diseases","volume":"8","author":"Kim","year":"2019","journal-title":"J Clin. Med."},{"key":"10.1016\/j.bcp.2026.117897_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114864","article-title":"Effects of flaxseed powder in improving non-alcoholic fatty liver by regulating gut microbiota-bile acids metabolic pathway through FXR\/TGR5 mediating","volume":"163","author":"Yang","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.bcp.2026.117897_b0205","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41579-022-00805-x","article-title":"Bile acids and the gut microbiota: metabolic interactions and impacts on disease","volume":"21","author":"Collins","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.bcp.2026.117897_b0210","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.997018","article-title":"Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications","volume":"12","author":"Fang","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"15","key":"10.1016\/j.bcp.2026.117897_b0215","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158343","article-title":"Interactive relationships between intestinal flora and bile acids","volume":"23","author":"Guo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.117897_b0220","first-page":"144","article-title":"Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma","volume":"21","author":"Song","year":"2023","journal-title":"Cancer Biol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0225","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12915-017-0462-7","article-title":"Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice","volume":"15","author":"Zheng","year":"2017","journal-title":"BMC Biol."},{"issue":"14","key":"10.1016\/j.bcp.2026.117897_b0230","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3748\/wjg.15.1677","article-title":"Bile-acid-induced cell injury and protection","volume":"15","author":"Perez","year":"2009","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117897_b0235","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/19490976.2020.1732268","article-title":"The microbiome modulating activity of bile acids","volume":"11","author":"Tian","year":"2020","journal-title":"Gut Microbes"},{"key":"10.1016\/j.bcp.2026.117897_b0240","article-title":"The 7-\u03b1-dehydroxylation pathway: an integral component of gut bacterial bile acid metabolism and potential therapeutic target","volume":"13","author":"Wise","year":"2022","journal-title":"Front. Microbiol."},{"issue":"10","key":"10.1016\/j.bcp.2026.117897_b0245","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102618","article-title":"Bile acids activate NLRP3 inflammasome, promoting murine liver inflammation or fibrosis in a cell type-specific manner","volume":"10","author":"Holtmann","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2026.117897_b0250","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7659509","article-title":"Role of bile acids in dysbiosis and treatment of nonalcoholic fatty liver disease","volume":"2019","author":"Wang","year":"2019","journal-title":"Mediators Inflamm."},{"issue":"3","key":"10.1016\/j.bcp.2026.117897_b0255","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000310","article-title":"Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease","volume":"8","author":"Long","year":"2024","journal-title":"Hepatol. Commun."},{"issue":"15","key":"10.1016\/j.bcp.2026.117897_b0260","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155214","article-title":"Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications","volume":"21","author":"Chen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.117897_b0265","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/apt.16948","article-title":"Circulating bile acid concentrations and non-alcoholic fatty liver disease in guatemala","volume":"56","author":"Rivera-Andrade","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2026.117897_b0270","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41401-022-00880-z","article-title":"Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease","volume":"43","author":"Jiao","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"28","key":"10.1016\/j.bcp.2026.117897_b0275","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.4254\/wjh.v7.i28.2811","article-title":"Bile acid receptors and nonalcoholic fatty liver disease","volume":"7","author":"Yuan","year":"2015","journal-title":"World J. Hepatol."},{"issue":"14","key":"10.1016\/j.bcp.2026.117897_b0280","doi-asserted-by":"crossref","DOI":"10.3390\/cells12141888","article-title":"Bile acids, intestinal barrier dysfunction, and related diseases","volume":"12","author":"Shi","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2026.117897_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2024.110024","article-title":"Role of FXR in the development of NAFLD and intervention strategies of small molecules","volume":"757","author":"Long","year":"2024","journal-title":"Arch. Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0290","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/aps.2014.117","article-title":"FXR and liver carcinogenesis","volume":"36","author":"Huang","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.101777","article-title":"From gut to liver: exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Zhou","year":"2025","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.bcp.2026.117897_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2023.109491","article-title":"Modulation of pectin on intestinal barrier function via changes in microbial functional potential and bile acid metabolism","volume":"124","author":"Yin","year":"2024","journal-title":"J. Nutr. Biochem."},{"issue":"4","key":"10.1016\/j.bcp.2026.117897_b0305","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1055\/s-0041-1731707","article-title":"Role of FXR in bile acid and metabolic homeostasis in NASH: pathogenetic concepts and therapeutic opportunities","volume":"41","author":"Radun","year":"2021","journal-title":"Semin. Liver Dis."},{"issue":"8","key":"10.1016\/j.bcp.2026.117897_b0310","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0315","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0320","first-page":"38","article-title":"Incidence and characterization of SIBO in NAFLD patients","volume":"15","author":"Naizr","year":"2025","journal-title":"Eur. J. Hepatogastroenterol."},{"issue":"24","key":"10.1016\/j.bcp.2026.117897_b0325","doi-asserted-by":"crossref","DOI":"10.3390\/nu14245261","article-title":"The prevalence of small intestinal bacterial overgrowth in patients with non-alcoholic liver diseases: NAFLD, NASH, fibrosis, cirrhosis-a systematic review, meta-analysis and meta-regression","volume":"14","author":"Gudan","year":"2022","journal-title":"Nutrients"},{"issue":"12","key":"10.1016\/j.bcp.2026.117897_b0330","doi-asserted-by":"crossref","first-page":"5583","DOI":"10.3390\/nu6125583","article-title":"The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease","volume":"6","author":"Ferolla","year":"2014","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/ceh.2019.83151","article-title":"Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease","volume":"5","author":"Augustyn","year":"2019","journal-title":"Clin. Exp. Hepatol."},{"key":"10.1016\/j.bcp.2026.117897_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115546","article-title":"The role of small intestinal bacterial overgrowth in obesity and its related diseases","volume":"212","author":"Yao","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117897_b0345","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1055\/s-0042-1748037","article-title":"Intestinal barrier dysfunction in fatty liver disease: roles of microbiota mucosal immune system, and bile acids","volume":"42","author":"Gupta","year":"2022","journal-title":"Semin. Liver Dis."},{"issue":"4","key":"10.1016\/j.bcp.2026.117897_b0350","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1039\/D2FO03015B","article-title":"Baicalein alleviates non-alcoholic fatty liver disease in mice by ameliorating intestinal barrier dysfunction","volume":"14","author":"Guo","year":"2023","journal-title":"Food Funct."},{"issue":"11","key":"10.1016\/j.bcp.2026.117897_b0355","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.202300910","article-title":"Gut epithelial barrier function is impacted by hyperglycemia and secondary bile acids in vitro: possible rescuing effects of specific pectins","volume":"68","author":"Tang","year":"2024","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.bcp.2026.117897_b0360","doi-asserted-by":"crossref","unstructured":"R. Forlano, B.H. Mullish, L.A. Roberts, M.R. Thursz, P. Manousou, The intestinal barrier and its dysfunction in patients with metabolic diseases and non-alcoholic fatty liver disease, 23(2) (2022) 662.","DOI":"10.3390\/ijms23020662"},{"issue":"4","key":"10.1016\/j.bcp.2026.117897_b0365","article-title":"Intestinal barrier dysfunction and gut microbiota in non-alcoholic fatty liver disease: assessment, mechanisms, and therapeutic considerations","volume":"13","author":"Long","year":"2024","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.bcp.2026.117897_b0370","doi-asserted-by":"crossref","unstructured":"Y. Wang, S. Cui, J. Zheng, Y. Li, P. Li, H. Hou, Berberine ameliorates intestinal mucosal barrier dysfunction in nonalcoholic fatty liver disease (NAFLD) rats, J. King Saud Univ.\u2013 Sci., 32.","DOI":"10.1016\/j.jksus.2020.03.019"},{"issue":"14","key":"10.1016\/j.bcp.2026.117897_b0375","doi-asserted-by":"crossref","DOI":"10.3390\/cells12141888","article-title":"Bile acids, intestinal barrier dysfunction, and related diseases","volume":"12","author":"Shi","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2026.117897_b0380","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1021924","article-title":"Bile acids as inflammatory mediators and modulators of intestinal permeability","volume":"13","author":"Calzadilla","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0385","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/TP.0000000000002480","article-title":"Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH","volume":"103","author":"Pierantonelli","year":"2019","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.bcp.2026.117897_b0390","doi-asserted-by":"crossref","DOI":"10.3390\/nu9101124","article-title":"Gut microbiota and nonalcoholic fatty liver disease: insights on mechanisms and therapy","volume":"9","author":"Ma","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.bcp.2026.117897_b0395","doi-asserted-by":"crossref","first-page":"287348","DOI":"10.1155\/2015\/287348","article-title":"Role of gut barrier function in the pathogenesis of nonalcoholic fatty liver disease","volume":"2015","author":"Dai","year":"2015","journal-title":"Gastroenterol Res. Pract."},{"issue":"22","key":"10.1016\/j.bcp.2026.117897_b0400","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.3748\/wjg.v23.i22.3954","article-title":"Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease","volume":"23","author":"Utzeri","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bcp.2026.117897_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2024.101980","article-title":"Free fatty acid induces apoptosis by targeting miR-26a in hepatic cells","volume":"14","author":"Sah","year":"2024","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2004.06.001","article-title":"Mitochondrially-mediated toxicity of bile acids","volume":"203","author":"Palmeira","year":"2004","journal-title":"Toxicology"},{"key":"10.1016\/j.bcp.2026.117897_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2021.100325","article-title":"Effect of bile acids on the expression of MRP3 and MRP4: an in vitro study in HepG2 cell line","volume":"24","author":"P\u00e9rez-Pineda","year":"2021","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.bcp.2026.117897_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2023.105596","article-title":"Organic selenium ameliorates non-alcoholic fatty liver disease through 5-hydroxytryptamine\/bile acid enterohepatic circulation in mice","volume":"106","author":"Zhang","year":"2023","journal-title":"J. Funct. Foods"},{"key":"10.1016\/j.bcp.2026.117897_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176193","article-title":"Glycyrrhetinic acid attenuates endoplasmic reticulum stress-induced hepatocyte apoptosis via CHOP\/DR5\/Caspase 8 pathway in cholestasis","volume":"961","author":"Zou","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117897_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120625","article-title":"Free fatty acid-induced miR-181a-5p stimulates apoptosis by targeting XIAP and Bcl2 in hepatic cells","volume":"301","author":"Yadav","year":"2022","journal-title":"Life Sci."},{"issue":"1\u20133","key":"10.1016\/j.bcp.2026.117897_b0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2004.06.001","article-title":"Mitochondrially-mediated toxicity of bile acids","volume":"203","author":"Palmeira","year":"2004","journal-title":"Toxicology"},{"issue":"6","key":"10.1016\/j.bcp.2026.117897_b0440","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1590-8658(02)80033-0","article-title":"Bile acid-mediated hepatocyte apoptosis and cholestatic liver disease","volume":"34","author":"Guicciardi","year":"2002","journal-title":"Dig. Liver Dis."},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0445","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.yexcr.2018.11.023","article-title":"Bile acid-induced apoptosis and bile acid synthesis are reduced by over-expression of augmenter of liver regeneration (ALR) in a STAT3-dependent mechanism","volume":"374","author":"Ibrahim","year":"2019","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bcp.2026.117897_b0450","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-3-030-49844-3_9","article-title":"Bile acid toxicity and protein kinases","volume":"1275","author":"Engin","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117897_b0455","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/hep.29411","article-title":"Beyond farnesoid X receptor to target new therapies for NAFLD","volume":"66","author":"Liu","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bcp.2026.117897_b0460","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR agonists for MASH therapy: lessons and perspectives from obeticholic acid","volume":"44","author":"Wang","year":"2024","journal-title":"Med. Res. Rev."},{"issue":"6","key":"10.1016\/j.bcp.2026.117897_b0465","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/hep.29305","article-title":"Small heterodimer partner deletion prevents hepatic steatosis and when combined with farnesoid X receptor loss protects against type 2 diabetes in mice","volume":"66","author":"Akinrotimi","year":"2017","journal-title":"Hepatology (Baltimore Md.)"},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0470","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"issue":"9972","key":"10.1016\/j.bcp.2026.117897_b0475","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.117897_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.06.017","article-title":"REGENERATE: DESIGN of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis","volume":"84","author":"Ratziu","year":"2019","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.bcp.2026.117897_b0485","article-title":"Effect of probiotics therapy on nonalcoholic fatty liver disease","volume":"2022","author":"Huang","year":"2022","journal-title":"Comput. Math. Methods Med."},{"key":"10.1016\/j.bcp.2026.117897_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104952","article-title":"Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid","volume":"100","author":"Lau","year":"2024","journal-title":"EBioMedicine"},{"issue":"19","key":"10.1016\/j.bcp.2026.117897_b0495","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914918","article-title":"Prebiotics and probiotics: therapeutic tools for nonalcoholic fatty liver disease","volume":"24","author":"Mijangos-Trejo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2026.117897_b0500","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","article-title":"Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"79","author":"Song","year":"2023","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.bcp.2026.117897_b0505","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/apt.12758","article-title":"Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis","volume":"39","author":"Alisi","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0510","doi-asserted-by":"crossref","DOI":"10.3390\/biom12010056","article-title":"Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives","volume":"12","author":"Vallianou","year":"2021","journal-title":"Biomolecules"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2026.117897_b0515","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1097\/MCG.0000000000000347","article-title":"Probiotics in nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and cirrhosis","volume":"49","author":"Qamar","year":"2015","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.bcp.2026.117897_b0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114564","article-title":"Short-chain fatty acids alleviate cholestatic liver injury by improving gut microbiota and bile acid metabolism","volume":"154","author":"Lu","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2026.117897_b0525","doi-asserted-by":"crossref","DOI":"10.3390\/nu10111793","article-title":"Gut permeability might be improved by dietary fiber in individuals with nonalcoholic fatty liver disease (NAFLD) undergoing weight reduction","volume":"10","author":"Krawczyk","year":"2018","journal-title":"Nutrients"},{"issue":"17","key":"10.1016\/j.bcp.2026.117897_b0530","doi-asserted-by":"crossref","DOI":"10.3390\/nu14173453","article-title":"Characterization of nutrient intake in biopsy-confirmed NAFLD patients","volume":"14","author":"Kamada","year":"2022","journal-title":"Nutrients"},{"issue":"12","key":"10.1016\/j.bcp.2026.117897_b0535","doi-asserted-by":"crossref","DOI":"10.3390\/nu13124438","article-title":"Dietary composition and its association with newly diagnosed nonalcoholic fatty liver disease and insulin resistance","volume":"13","author":"Charatcharoenwitthaya","year":"2021","journal-title":"Nutrients"},{"issue":"19","key":"10.1016\/j.bcp.2026.117897_b0540","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.3748\/wjg.v24.i19.2083","article-title":"Mediterranean diet and nonalcoholic fatty liver disease","volume":"24","author":"Anania","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0545","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s42000-021-00339-6","article-title":"Nonalcoholic fatty liver disease: lifestyle and quality of life","volume":"21","author":"Vachliotis","year":"2022","journal-title":"Hormones"},{"issue":"8","key":"10.1016\/j.bcp.2026.117897_b0550","doi-asserted-by":"crossref","DOI":"10.3390\/nu9080800","article-title":"Dietary composition independent of weight loss in the management of non-alcoholic fatty liver disease","volume":"9","author":"Eslamparast","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.bcp.2026.117897_b0555","doi-asserted-by":"crossref","first-page":"1038435","DOI":"10.3389\/fpubh.2022.1038435","article-title":"Dietary fiber intake and non-alcoholic fatty liver disease: the mediating role of obesity","volume":"10","author":"Zhu","year":"2022","journal-title":"Front Public Health"},{"issue":"3","key":"10.1016\/j.bcp.2026.117897_b0560","doi-asserted-by":"crossref","DOI":"10.3390\/nu12030699","article-title":"Adipokines and endotoxemia correlate with hepatic steatosis in non-alcoholic fatty liver disease (NAFLD)","volume":"12","author":"Nier","year":"2020","journal-title":"Nutrients"},{"issue":"11","key":"10.1016\/j.bcp.2026.117897_b0565","doi-asserted-by":"crossref","DOI":"10.3390\/foods13111683","article-title":"Polyphenols from foxtail millet improve non-alcoholic fatty liver disease by regulating intestinal microbiome in mice","volume":"13","author":"Ghani","year":"2024","journal-title":"Foods"},{"issue":"2","key":"10.1016\/j.bcp.2026.117897_b0570","doi-asserted-by":"crossref","DOI":"10.3390\/nu13020494","article-title":"Dietary polyphenols and non-alcoholic fatty liver disease","volume":"13","author":"Abenavoli","year":"2021","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.bcp.2026.117897_b0575","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/agriculture13020249","article-title":"The phytochemical synergistic properties of combination of bergamot polyphenolic fraction and cynara cardunculus extract in non-alcoholic fatty liver disease","volume":"13","author":"Maiuolo","year":"2023","journal-title":"Agriculture"},{"issue":"26","key":"10.1016\/j.bcp.2026.117897_b0580","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.2174\/0929867329666221007115809","article-title":"Targeting mitochondria for the prevention and treatment of nonalcoholic fatty liver disease: polyphenols as a non-pharmacological approach","volume":"30","author":"Jaime","year":"2023","journal-title":"Curr. Med. Chem."},{"issue":"16","key":"10.1016\/j.bcp.2026.117897_b0585","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117897_b0590","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","article-title":"Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review","volume":"66","author":"Hashida","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2026.117897_b0595","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820941745","article-title":"The role of the gut microbiome and exercise in non-alcoholic fatty liver disease","volume":"13","author":"Houttu","year":"2020","journal-title":"Therap. Adv. Gastroenterol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117897_b0600","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s13679-019-00345-1","article-title":"Nonalcoholic fatty liver disease and obesity treatment","volume":"8","author":"Brunner","year":"2019","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.bcp.2026.117897_b0605","doi-asserted-by":"crossref","first-page":"1162485","DOI":"10.3389\/fendo.2023.1162485","article-title":"Exercise intervention improves mitochondrial quality in non-alcoholic fatty liver disease zebrafish","volume":"14","author":"Zou","year":"2023","journal-title":"Front Endocrinol. (Lausanne)"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226002303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226002303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:19:22Z","timestamp":1778710762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226002303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":121,"alternative-id":["S0006295226002303"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117897","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanism and interventions of the bile acid-gut-liver axis imbalance in the progression of non-alcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117897"}}